Published date: 22 November 2021

Closed opportunity - This means that the contract is currently closed. The buying department may be considering suppliers that have already applied, or no suitable offers were made.


Closing: 5 January 2022, 1pm

Contract summary

Industry

  • Syringes - 33141310

  • Medical needles - 33141320

  • Pharmaceutical products - 33600000

    • Medicinal products for the blood and blood-forming organs - 33621000

    • Antihaemorrhagics - 33621200

    • Clinical products - 33698000

    • Glass ampoules - 39299100

    • Cartons - 44617100

    • Packaging and related services - 79920000

Location of contract

London

Value of contract

£900,000 to £975,000

Procurement reference

20211122190045-104519

Published date

22 November 2021

Closing date

5 January 2022

Closing time

1pm

Contract start date

1 April 2022

Contract end date

30 April 2025

Contract type

Supply contract

Procedure type

Open procedure

Any interested supplier may submit a tender in response to an opportunity notice.

Contract is suitable for SMEs?

Yes

Contract is suitable for VCSEs?

No

Description

Manufacturing and packing of IMP for the IM Woman Trial due to commence in March 2023.

A randomised, triple-blind, three-arm, non-inferiority trial to assess the efficacy and safety of intramuscular tranexamic acid compared to intravenous tranexamic acid and placebo in women having vvaginal and caesarean section births.

Three arms include experimental treatment (IM TXA), reference treatment/active control (IV TXA), and placebo control (0.9% sodium chloride solution).

Provision of treatment kit boxes required for 4 campaigns with approximately 10,000 patient packs per campaign. Recruitment period is 24 months - campaign approximately once every 6 months commencing March 2023.

More information

Links

About the buyer

Contact name

Paul Pester

Address

Keppel Street,
London
WC1E 7HT
ENG

Telephone

+44 02079272471

Email

paul.pester@lshtm.ac.uk

Website

www.lshtm.ac.uk